Patents by Inventor Justin A. Kenkel
Justin A. Kenkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406939Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: ApplicationFiled: July 21, 2023Publication date: December 21, 2023Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin ACKERMAN, David DORNAN, Karla A. HENNING, Justin A. KENKEL
-
Patent number: 11753474Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: GrantFiled: February 3, 2022Date of Patent: September 12, 2023Assignee: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
-
Publication number: 20230111340Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: ApplicationFiled: August 8, 2022Publication date: April 13, 2023Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20230086603Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 23, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20230069055Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 2, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Patent number: 11547761Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: GrantFiled: September 3, 2021Date of Patent: January 10, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20220226491Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220153849Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: ApplicationFiled: February 3, 2022Publication date: May 19, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
-
Publication number: 20220143012Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Patent number: 11110178Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: GrantFiled: March 13, 2020Date of Patent: September 7, 2021Assignees: The Board of Trustees of the Leland Standford Junior University, BOLT BIOTHERAPEUTICS, INC.Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20200206357Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: ApplicationFiled: March 13, 2020Publication date: July 2, 2020Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Patent number: 10675358Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: GrantFiled: September 24, 2018Date of Patent: June 9, 2020Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20200140556Abstract: Provided are methods and compositions for treating an individual with cancer or infectious disease. Multivalent Dectin-2 stimulating agents are provided that include: (a) an agent that binds to Dectin-2 and stimulates Dectin-2 signaling; and (b) an antibody and/or an immunomodulatory agent, wherein (a) and (b) are conjugated to one another. In some cases, (a) is a mannobiose glycopolypeptide that binds to Dectin-2. In some cases (b) is a stimulatory ligand for a TLR (e.g., TLR7, TLR8, TLR7/8, TLR2, and the like). Methods of treating an individual with cancer and/or an infectious disease can include administering to the individual an effective amount of a Dectin-2 stimulating composition. In some cases, the Dectin-2 stimulating composition comprises a Dectin-2 stimulating glycopolymer. In some cases the Dectin-2 stimulating composition comprises a multivalent Dectin-2 stimulating agent.Type: ApplicationFiled: June 27, 2018Publication date: May 7, 2020Inventors: Justin KENKEL, Matthew ZHOU, Shelley Erin ACKERMAN, Edgar George ENGLEMAN, Michael Nathaniel ALONSO, Carolyn R. BERTOZZI
-
Publication number: 20190076547Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via, the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: ApplicationFiled: September 24, 2018Publication date: March 14, 2019Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20190010236Abstract: Provided are methods and compositions for treating an individual with cancer by administering to the individual a composition that includes a Dectin-2 stimulating agent that stimulates Dectin-2 signaling in myeloid cells (e.g., induces Dectin-2 clustering on the cell surface), thereby stimulating an anti-cancer immune response in the individual. In some cases, the myeloid cells are tumor-associated myeloid (TAM) cells. Methods and compositions are also provided for: treating an individual with cancer via contacting a cancer cell from the individual with an alpha-mannosidase class 1 inhibitor (e.g.Type: ApplicationFiled: December 28, 2016Publication date: January 10, 2019Inventors: Justin Kenkel, Carolyn R. Bertozzi, Edgar George Engleman